Abstracts tagged "Biomarkers"

Abstract Number: 589 • 2016 ACR/ARHP Annual Meeting
Netosis-Derived Products Might Have Diagnostic Potential for Disease Activity, Atherosclerosis and Analysis of Therapeutic Effectiveness in Rheumatoid Arthritis Patients
Chary Lopez-Pedrera¹, Patricia Ruiz-Limon², Carlos Perez-Sanchez¹, Yolanda Jiménez-Gómez¹, Maria Carmen Abalos-Aguilera², Ivan Arias de la Rosa¹, Pedro Segui¹, Pilar Font-Ugalde¹, Maria Ángeles Aguirre Zamorano¹, Jerusalem Calvo-Gutierrez¹, Rafaela Ortega-Castro¹, M. Carmen Castro-Villegas³, Rocio Gonzalez-Conejero⁴, Constantino Martinez⁴, Eduardo Collantes-Estévez¹, Alejandro Escudero-Contreras² and Nuria Barbarroja¹, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴Regional Centre for Blood Donation, University of Murcia, Murcia, Spain
Background/Purpose: Neutrophil extracellular traps (NETs) have recently been implicated in vascular damage and atherothrombosis. Extruded DNA fibers containing multiple proinflammatory and thrombotic molecules induce the…
Abstract Number: 1207 • 2016 ACR/ARHP Annual Meeting
Design of a Multiplex Serum Proteome Assay to Monitor Biologic Drug Response in Rheumatoid Arthritis Patients
Niamh Callan¹, Aisha Butt¹, Stephen R. Pennington², Cathy McGeough³, Philip Gardiner⁴, Gary Wright⁵, Tony Bjourson³ and David S. Gibson⁶, ¹Proteome Research Centre, Conway Institute, University College Dublin, Dublin, Ireland, ²Proteome Research Centre, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ³Northern Ireland Centre for Stratified Medicine, Ulster University, Londonderry, United Kingdom, ⁴Rheumatology, Altnagelvin Hospital, Londonderry, United Kingdom, ⁵Rheumatology, Musgrave Park Hospital, BELFAST, United Kingdom, ⁶Inflammatory Disease Research Group, Northern ireland Centre for Stratified Medicine, Ulster University, Londonderry, United Kingdom
Background/Purpose: Biologic drugs have revolutionised the treatment of Rheumatoid Arthritis (RA), however these therapies are expensive and exhibit a high non–response rate (30%). Currently there…
Abstract Number: 1865 • 2016 ACR/ARHP Annual Meeting
Urinary Cell Adhesion Molecules As Markers of Renal Involvement in Systemic Sclerosis
Edward Stern¹, Voon H. Ong², Aine Burns³, Robert Unwin⁴ and Christopher Denton⁵, ¹UCL Division of Medicine, London, United Kingdom, ²Rheumatology, UCL Division of Medicine, London, United Kingdom, ³Nephrology, Royal Free Hospital, London, United Kingdom, ⁴Nephrology, UCL Division of Medicine, London, United Kingdom, ⁵Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom
Background/Purpose: Renal involvement in systemic sclerosis (SSc) includes scleroderma renal crisis as well as progressive organ fibrosis. Detection and management of these disease complications is…
Abstract Number: 2428 • 2016 ACR/ARHP Annual Meeting
Autoantibody Diversity in Pediatric Patients Undergoing Evaluation for Autoimmune Encephalitis: A Retrospective Investigation
Anne E Tebo¹, Thomas Haven², Aimee O. Hersh³ and Eyal Muscal⁴, ¹Pathology, University of Utah School of Medicine and ARUP Laboratories, Salt Lake City, UT, ²Department of Pathology, University of Utah, ARUP Institute of Clinical and Experimental Pathology, Salt Lake City, UT, ³Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁴Immunology, allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Antibodies directed against N-methyl-D-aspartate type glutamate receptor (NMDAR), voltage-gated potassium channel (VGKC) or glutamic acid decarboxylase (GAD65) are frequently associated with autoimmune encephalitis (AE)…
Abstract Number: 2848 • 2016 ACR/ARHP Annual Meeting
Near Patient Anti-Nuclear Antibody Multiplex Testing Using Whole Blood for the Diagnosis of Connective Tissue Diseases in a Tertiary Care Center
Makoto Miyara¹, Jean- Luc Charuel², Sasi Mudumba³, Alice Wu³, Pascale Ghillani-Dalbin², Zahir Amoura^4,5,6, Rufus Burlingame⁷ and Lucile Musset¹, ¹Department of immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ²Department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Genalyte, Inc., San Diego, CA, ⁴Internal Medecine - Centre de Référence National pour les Lupus et et le Syndrome des Antiphospholipides, Internal Medecine - Centre de Référence National pour les Lupus et et le Syndrome des Antiphospholipides, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ⁵Department of Internal Medicine 2. Referal center for SLE/APS, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ⁶Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ⁷Genaltye, San Diego, CA
Background/Purpose: Detection of anti-nuclear antibodies for the diagnosis of connective tissue diseases (CTD) often requires complex algorithms to obtain conclusive results , including immunofluorescence on…
Abstract Number: 3250 • 2016 ACR/ARHP Annual Meeting
Serum MCP-1 Levels Predict Long-Term Progression of Interstitial Lung Disease in Systemic Sclerosis
Minghua Wu¹, Murray Baron², Marie Hudson³, Marvin J. Fritzler⁴, Claudia Pedroza⁵, Jun Ying¹, Gloria Salazar¹, Julio Charles⁶, Maureen D Mayes¹ and Shervin Assassi¹, ¹Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ²Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ³Rheumatology, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁴Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁵Pediatrics, University of Texas-McGovern Medical School, Houston, TX, ⁶Internal Medicine-Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Currently available clinical biomarkers are not reliable predictors of long-term progression of interstitial lung disease (ILD) in the context of systemic sclerosis (SSc) A previous…
Abstract Number: 39 • 2016 ACR/ARHP Annual Meeting
Effects of Pregabalin (Lyrica®) on Cerebrospinal Fluid Substance P in Human Subjects with Fibromyalgia Syndrome
Irwin Jon Russell¹, Joel E. Michalek² and Sorleen Trevino-Mendez³, ¹Affiliated with Arthritis & Osteoporosis Center of South Texas, Medical Director, Fibromyalgia Research and Consulting, San Antonio, Texas, San Antonio, TX, ²Professor, Department of Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio, San Antonio, Texas, San Antonio, TX, ³Medical Student, Texas Tech University School of Medicine, Lubbock, TX
Background/Purpose: Fibromyalgia Syndrome [FMS] is a common chronic pain disorder. Pregabalin (PGB) is one of three medications approved by the FDA for treatment of FMS.…
Abstract Number: 647 • 2016 ACR/ARHP Annual Meeting
Genomic and Epigenetic Bioinformatics Demonstrate Dual TNF-α and IL17A Target Engagement By ABT-122, and Suggest Mainly TNF-α–Mediated Relative Target Contribution to Drug Response in MTX-IR Rheumatoid Arthritis Patients
Robert W. Georgantas III¹, Melanie Ruzek², Justin Wade Davis¹, Feng Hong¹, Elizabeth Asque¹, Kenneth Idler¹, Heikki T. Mansikka¹, Benoit Guerette¹ and Jeffrey F. Waring¹, ¹AbbVie Inc., North Chicago, IL, ²Immunology Discovery, AbbVie, Worcester, MA
Background/Purpose: ABT-122 is a dual variable domain (DVD-Ig) biologic which inhibits TNF-α and IL17A. In a 12-wk phase 2 study (NCT02141997) in MTX-IR patients (pts)…
Abstract Number: 1219 • 2016 ACR/ARHP Annual Meeting
Differential Peripheral Blood DNA Methylation Patterns Are Predictive of Radiographic OA Progression
Matlock A. Jeffries¹, Madison Andrews², Judith A. James³, Mary Beth Humphrey⁴ and Amr H. Sawalha⁵, ¹Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Medicine/Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Extensive evidence has correlated epigenetic alterations in articular tissues with both the presence and progression of human osteoarthritis, but data regarding extraarticular tissues are…
Abstract Number: 1871 • 2016 ACR/ARHP Annual Meeting
Predicting Vascular Complications in Systemic Sclerosis: A Prospective Cohort Study
Christopher A. Mecoli¹, Ami A. Shah², Francesco Boin³, Fredrick M. Wigley⁴ and Laura K. Hummers¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, University California San Francisco, San Francisco, CA, ⁴Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Vascular disease is of fundamental importance in the pathogenesis of scleroderma. Two major vascular complications in scleroderma patients that cause substantial morbidity and mortality…
Abstract Number: 2496 • 2016 ACR/ARHP Annual Meeting
DMARD, Biologic and Small Molecule Drug Use Among ACPA Positive and ACPA Negative RA Patients in a Tertiary Referral Center
Richard Meehan¹, Eric Hoffman², David Muram³, Barbara Goldstein⁴, Jim Crooks⁵ and Pearlanne Zelarney⁶, ¹MEDICINE, National Jewish Health, Denver, CO, ²Medicine/Rheumjatology, National Jewish Health, denver, CO, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology, National Jewish Health, Denver, CO, ⁵Biostatistics, National Jewish Health, Denver, CO, ⁶Bioinformatics, National Jewish Health, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) can be divided into two major subsets based on the presence or absence of antibodies to citrullinated peptide antigens (ACPA). Some…
Abstract Number: 2858 • 2016 ACR/ARHP Annual Meeting
Urinary PF4 and E-Selectin As Novel Biomarkers for Disease Activity and Renal Damage in Lupus Nephritis
Huihua Ding¹, Ling Qin¹, Samantha Stanley¹, Ramesh Saxena² and Chandra Mohan³, ¹Biomedical Engineering Department, University of Houston, Houston, TX, ²Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, ³Biomedical Engineering, University of Houston, Houston, TX
Background/Purpose: Lupus nephritis (LN) is the leading cause of morbidity and mortality in systemic lupus erythematosus (SLE). The objective of this study is to validate…
Abstract Number: 63 • 2016 ACR/ARHP Annual Meeting
Identification of Immune Gene Modules in Good Responders to Adalimumab in Rheumatoid Arthritis
James OIiver¹, Darren Plant², Gisela Orozco¹, Samantha Smith¹, Kimme L. Hyrich³, Ann Morgan⁴, John Isaacs⁵, Anthony G. Wilson⁶ and Anne Barton^1,2, ¹Arthritis Research UK, Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust, Manchester, United Kingdom, ³Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, ⁵Institute of Cellular Medicine, Newcastle University and National Institute for Health Research Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, ⁶UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland
Background/Purpose: Despite the revolutionary impact of TNF inhibitor (TNFi) therapy in rheumatoid arthritis (RA), up to 40% of patients fail to respond adequately. Whilst non-responder…
Abstract Number: 728 • 2016 ACR/ARHP Annual Meeting
Correlation Between the Spinal MRI Findings and the Serum Level of DKK-1 in Patients with Spondyloarthritis Treated with TNF Antagonist
Zheng Zhao, Gang Wang, Yanyan Wang, Jinshui Yang, Jian Zhu and Feng Huang, Rheumatology, Chinese PLA General Hospital, Beijing, China
Background/Purpose : Recent prospective data suggest that spinal inflammatory damage in patients with ankylosing spondylitis will eventually convert into fat. In these complex inflammatory lesions,…
Abstract Number: 1247 • 2016 ACR/ARHP Annual Meeting
Diagnostic Modeling of Rheumatoid Arthritis in Oklahoma Tribal Members Using Soluble Mediators
Lucas Adams¹, Carla J. Guthridge¹, Tim Gross¹, Hua Chen¹, Krista M. Bean¹, Virginia C. Roberts¹, Julie M. Robertson², Melissa E. Munroe¹, Joel M. Guthridge³, Roger Montgomery⁴, M. Sohail Khan⁴, Fabio Mota⁵, Michael Peercy⁶, Bobby Saunkeah⁷ and Judith A. James^8,9, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Acelity, San Antonio, TX, ³Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Cherokee Nation Health Services, Tahlequah, OK, ⁵Chickasaw Nation Medical Center, Ada, OK, ⁶Epidemiology, Chickasaw Nation Department of Health, Ada, OK, ⁷Chickasaw Nation Department of Health, Ada, OK, ⁸Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Diagnosis of RA is difficult in American Indian (AI) patients who often have atypical autoantibodies (e.g. ANA) with erosive arthritis. Soluble mediators may serve…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].